• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Drugs to be offered to women at high risk of breast cancer
The National Institute of Health and Care Excellence (NICE) has today released updated guidelines on the care of women who are at increased risk of breast cancer due to their family history. One of the main changes to the original guidance from 2004 is that NICE now recommends drug treatment with tamoxifen or raloxifene to reduce risk of breast cancer in a specific group of women who are at high risk of breast cancer and have not had the disease. They say that these treatments could help prevent breast cancer in about 488,000 women aged 35 years and older. The updated guideline has also made changes to the recommende...
Source: NHS News Feed - June 25, 2013 Category: Consumer Health News Tags: Cancer Medical practice QA articles Source Type: news

Time trends in pulmonary embolism: A matter of age and gender
Venous thromboembolism (VTE) is the third most common cardiovascular disease . Pulmonary embolism (PE) is potentially lethal and is the most serious manifestation of VTE . Notably, PE is the leading preventable cause of death in hospitalized patients , and is the third most common cardiovascular cause of death after myocardial infarction and stroke in Western world . Risk factors for VTE and PE include old age, surgery, immobilization, trauma, fractures, cancer, pregnancy, puerperium, oral contraceptive pill (OCP) use, and hormone replacement therapy (HRT) . Genetic factors are also important in VTE risk and family history...
Source: Thrombosis Research - June 24, 2013 Category: Hematology Authors: Bengt Zöller Tags: Editorials Source Type: research

The Timing Hypothesis and Hormone Replacement Therapy: A Paradigm Shift in the Primary Prevention of Coronary Heart Disease in Women. Part 2: Comparative Risks
A major misperception concerning postmenopausal hormone replacement therapy (HRT) is that the associated risks are large in magnitude and unique to HRT, but over the past 10 years, sufficient data have accumulated so that the magnitude and perspective of risks associated with the primary coronary heart disease prevention therapies of statins, aspirin, and postmenopausal HRT have become more fully defined. Review of randomized controlled trials indicates that the risks of primary prevention therapies and other medications commonly used in women's health are of similar type and magnitude, with the majority of these risks ca...
Source: Journal of the American Geriatrics Society - May 20, 2013 Category: Geriatrics Authors: Howard N. Hodis, Wendy J. Mack Tags: Updates on Aging Source Type: research

Hormone therapy not recommended for chronic disease prevention in menopausal women
Commentary on: Nelson HD, Walker M, Zakher B, et al.. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the US Preventive Services Task Force recommendations. Ann Intern Med 2012;157:104–13. Context In 2005, the US Preventive Services Task Force (USPSTF) updated its 2002 hormone replacement therapy recommendations, advising against the routine use of oestrogen and progestin (E+P) and unopposed oestrogen (E) to prevent chronic conditions in menopausal women. Menopausal hormone therapy (MHT) had been commonly prescribed to prevent conditions such as cardiovascula...
Source: Evidence-Based Medicine - May 15, 2013 Category: Internal Medicine Authors: Wenger, N. K. Tags: Pancreas and biliary tract, Epidemiologic studies, Drugs: cardiovascular system, Dementia, Stroke, Contraception, Drugs: obstetrics and gynaecology, Menopause (including HRT), Ischaemic heart disease, Venous thromboembolism, Memory disorders (psychiatry), Source Type: research

In recently postmenopausal women, HRT reduced a composite of death, MI, or heart failure at 10 years.
CONCLUSION In recently postmenopausal women, hormone replacement therapy reduced a composite of death, myocardial infarction, or heart failure after 10 years of therapy and an additional 6 years of follow-up.Hormone replacement therapy (HRT) vs no HRT in recently postmenopausal women†OutcomesEvent ratesAfter 10 y of therapyHRTNo HRTRRR (95% CI)NNT (CI)Death, MI, or HF‡3.2%6.5%50% (11 to 72)31 (22 to 144)At 16 yDeath, MI, or HF§6.6%11%37% (4 to 59)26 (17 to 251)†HF = heart failure; MI = myocardial infarction; other abbreviations defined in Glossary. RRR, NNT, and CI calculated from event rates and hazard ratios in ar...
Source: Annals of Internal Medicine - February 19, 2013 Category: Internal Medicine Authors: Cheung AM Tags: Ann Intern Med Source Type: research

Pages: 1  2  3  4  5